Rivaroxaban

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
Rivaroxaban ʻO ka lāʻau anticoagulant I-Hale TDP    


Huahana Huahana

Huahana Huahana

NUI HUA

Kāpae

Rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2 -carboxamide, he mea hoʻopaneʻe liʻiliʻi liʻiliʻi ikaika o ka factor Xa he kumu coagulation i kahi manawa koʻikoʻi i ke ala coagulation koko e hopena ai i ka hana o ka thrombin a me ka hoʻokumu ʻana o ka clot. Hoʻopaʻa ʻo Rivaroxaban i ka Tyr288 ma ka ʻeke S1 o ka helu Xa ma o ka launa pū ʻana o Tyr288 a me ka chlorine substituent o ka chlorothiophene moiety. Hiki ke hoʻohuli ʻia ka inhibition (koff = 5x10-3s-1), wikiwiki (kon = 1.7x107 mol/L-1 s-1), a ma ke ʻano hilinaʻi (Ki = 0.4 nmol/L). Ke aʻo ʻia nei ʻo Rivaroxaban no ka mālama ʻana i ka VTE, ka pale ʻana i nā hanana cardiovascular i nā poʻe maʻi me ka maʻi coronary acute, ka pale ʻana i ka hahau i nā maʻi me ka fibrillation atrial.

Kuhikuhi

ʻO Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Wolfgang Mueck, a me Volker Laux. ʻO Rivaroxaban: kahi mea paʻa oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30(3): 376-381

wehewehe

ʻO Rivaroxaban (BAY 59-7939) kahi mea ikaika loakoho a pololei Factor Xa (FXa) inhibitor, e loaʻa i ka ikaika loaʻa i ka anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).

 

In Vitro

ʻO Rivaroxaban (BAY 59-7939) he waha, pololei Factor Xa (FXa) inhibitor i ka hoʻomohala ʻana no ka pale ʻana a me ka mālama ʻana i ka thrombosis arterial a me venous. ʻO Rivaroxaban ka hoʻokūkū hoʻokūkū i ka FXa kanaka (Ki 0.4 nM) me ka> 10 000-fold ka koho nui aʻe ma mua o nā proteases serine; ke pale aku nei i ka hana prothrombinase (IC50 2.1 nM). Rivaroxaban inhibits endogenous FXa oi potently i loko o kanaka a me ka rabbit plasma (IC50 21 nM) ma mua o rat plasma (IC50 290 nM). Hōʻike ia i nā hopena anticoagulant i loko o ka plasma kanaka, pālua ka manawa prothrombin (PT) a hoʻāla i ka manawa thromboplastin hapa ma 0.23 a me 0.69μM, kēlā me kēia.

 

ʻO Rivaroxaban (BAY 59-7939) he mea ikaika a koho, kuhikuhi FXa inhibitor me ka maikaʻi o ka hana vivo a me ka bioavailability waha. Rivaroxaban (BAY 59-7939), lawelawe ʻia e iv bolus ma mua o ka hoʻokomo ʻana i ka thrombus, hoʻemi i ka hoʻokumu ʻana o ka thrombus (ED50 0.1 mg / kg), hoʻopaʻa i ka FXa, a hoʻolōʻihi i ka dosis PT ma muli o ka hilinaʻi. Hoʻopilikia iki ʻia ʻo PT a me FXa i ka ED50 (1.8-fold piʻi a me 32% inhibition, kēlā me kēia). Ma ka 0.3 mg / kg (ka hopena e alakaʻi i ka hoʻopau piha ʻana i ka hoʻokumu ʻana o ka thrombus), hoʻolōʻihi ʻia ʻo Rivaroxaban i ka PT (3.2±0.5-fold) a pale i ka hana FXa (65±3%).

 

Waihona

Pauda

-20°C

3 makahiki
 

4°C

2 makahiki
I ka solvent

-80°C

6 mahina
 

-20°C

1 mahina

ʻO ke kinona

Rivaroxaban

HOOLAHA ANOAI

Hoʻoponopono maikaʻi1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.

Hoʻoponopono maikaʻi2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Hoʻoponopono maikaʻi3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Hoʻoponopono maikaʻi4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana o DCS

HOA

Ka launa pū ʻana o ka honua
Ka launa pū ʻana o ka honua
ʻO ka launa pū ʻana o ka home
ʻO ka launa pū ʻana o ka home

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou

    Māhele huahana